Some literatures have suggested that sorefenib may have a bifunction in suppressing the effects of VEGF and reducing tumor angiogenesis, resulting in increased ischemic hypoxia in the tumor tissue and slowed growth [44]. This evidence concerns the gene VEGFA and neoplasm.